Healthcare Sector Outpaces S&P 500 by 16 Points: One Stock with Momentum, Two Facing Pressure

Healthcare's Six-Month Surge Puts Spotlight on Stock Selection

The healthcare sector has been one of the standout performers of 2026, posting a 27.5% gain over the past six months — outpacing the S&P 500 by a notable 16.2 percentage points. That kind of outperformance naturally draws investor attention, but it also raises an important question: which companies are driving genuine value, and which are simply riding the sector's rising tide?

With drug development breakthroughs and digital health innovation reshaping the industry, selectivity matters more than ever. Heavy regulatory exposure can swing earnings in unpredictable ways, making fundamental analysis critical for navigating this space.

DexCom Shows Consistent Organic Growth

Among the companies analysts are watching closely, DexCom (DXCM) stands out for its operational fundamentals. Founded in 1999 and receiving its first FDA clearance in 2006, the San Diego-based company makes continuous glucose monitoring (CGM) systems — devices that allow diabetes patients to track blood sugar levels in real time, eliminating the need for repetitive finger-prick testing.

DexCom's financial profile reflects a business gaining meaningful traction. Organic revenue growth has averaged 12% annually over the past two years, a figure that suggests the company is expanding through its core operations rather than relying on acquisitions to pad results. Perhaps more telling is the trajectory of its free cash flow margin, which has expanded by 20.2 percentage points over the past five years — a sign of improving operational efficiency and increasing financial flexibility.

Returns on capital are also trending upward, suggesting management is allocating resources into increasingly productive investments. At a current share price of $89.41, DXCM trades at approximately 31.9x forward earnings — a premium valuation that reflects market confidence in the company's growth trajectory.

Centene Struggles with Customer Growth and Capital Returns

On the other side of the ledger, Centene (CNC) presents a more complicated picture. The managed care giant serves nearly one in every fifteen Americans through government-sponsored health programs, including Medicaid and Medicare for low-income and medically complex populations — a mission-critical role in the U.S. healthcare ecosystem.

However, the company's financial metrics raise questions. Customer growth has been inconsistent over the past two years, a pattern that may reflect intensifying competition for government contracts. More concerning are the company's returns on capital, which have turned negative — indicating that expansion efforts have not been generating adequate returns. Data suggests those returns are also declining from an already weak baseline, pointing to potential issues with capital allocation strategy.

At $64.74 per share, CNC trades at 14x forward earnings — a relatively modest multiple, but one that analysts note may reflect the underlying challenges rather than represent a straightforward value opportunity.

Mettler-Toledo Faces Growth Deceleration

Mettler-Toledo (MTD), the precision instrument manufacturer with roots in Swiss engineering innovation, rounds out the companies facing notable headwinds. The company produces high-precision weighing instruments, analytical tools, and product inspection systems used across laboratory, industrial, and food retail environments.

Despite operating in a specialized niche, MTD's recent growth numbers have disappointed relative to benchmarks. Organic revenue expansion has lagged expectations over the past two years, and Wall Street's forward estimates project only modest growth of 4.9% over the next 12 months — hardly the kind of acceleration that typically justifies a premium valuation. Returns on capital have also been shrinking, a signal that competitive pressures may be compressing the company's profit margins.

Mettler-Toledo currently trades at $1,426 per share, representing a 28.2x forward price-to-earnings multiple — an elevated valuation given the tepid growth outlook.

What Investors Should Watch

The broader healthcare sector's strong six-month run has created a mixed environment: genuine innovators like DexCom benefit from structural tailwinds in chronic disease management, while companies like Centene and Mettler-Toledo face pressures that their valuations may not fully reflect.

For the CGM market specifically, rising diabetes prevalence globally continues to expand the addressable market for companies like DexCom. Meanwhile, Centene's performance will likely hinge on Medicaid enrollment trends and the competitive dynamics of government contracting cycles — both of which remain subject to policy-level uncertainty.

With healthcare continuing to outperform broader markets, the sector's momentum is real — but as always, performance at the index level doesn't guarantee results at the individual company level.